We are live on ! Find out more
BG

Bollard Group Portfolio holdings

AUM $3.39B
1-Year Est. Return 1.06%
This Fund
S&P 500
This Quarter Est. Return
+5.29%
1 Year Est. Return
-1.06%
3 Year Est. Return
+72.63%
5 Year Est. Return
+112.03%
10 Year Est. Return
+415.67%
AUM
$2.69B
AUM Growth
-$89.6M
Cap. Flow
-$179M
Cap. Flow %
-6.67%
Top 10 Hldgs %
65.16%
Holding
456
New
11
Increased
34
Reduced
132
Closed
15

Top Sells

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$26.2M
2
DKNG icon
DraftKings
DKNG
+$22.6M
3
BA icon
Boeing
BA
+$19M
4
T icon
AT&T
T
+$14.8M
5
EPD icon
Enterprise Products Partners
EPD
+$9.88M

Sector Composition

Rank Sector Weight
1 Healthcare 46.28%
2 Consumer Discretionary 10.5%
3 Technology 8.37%
4 Communication Services 7.49%
5 Utilities 7.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HZNP
401
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$15K ﹤0.01%
+200
New +$14.9K
PRTK
402
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$14K ﹤0.01%
2,159
KIN
403
DELISTED
Kindred Biosciences, Inc.
KIN
$13K ﹤0.01%
3,129
KDP icon
404
Keurig Dr Pepper
KDP
$43B
$12K ﹤0.01%
367
+1
+0.3% +$30
LAB icon
405
Standard BioTools
LAB
$351M
$12K ﹤0.01%
1,975
SIEN
406
DELISTED
Sientra, Inc.
SIEN
$12K ﹤0.01%
308
MYO icon
407
Myomo
MYO
$38.6M
$11K ﹤0.01%
1,570
PFIE
408
DELISTED
Profire Energy, Inc
PFIE
$11K ﹤0.01%
12,822
DELL icon
409
Dell
DELL
$262B
$9K ﹤0.01%
235
EWJ icon
410
iShares MSCI Japan ETF
EWJ
$22.1B
$8K ﹤0.01%
123
+1
+0.8% +$63
GMAB icon
411
Genmab
GMAB
$17.6B
$8K ﹤0.01%
+200
New +$7.48K
ZBH icon
412
Zimmer Biomet
ZBH
$18.4B
$8K ﹤0.01%
50
JNCE
413
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$7K ﹤0.01%
1,009
UMC icon
414
United Microelectronic
UMC
$47.5B
$6K ﹤0.01%
+700
New +$4.57K
CTMX icon
415
CytomX Therapeutics
CTMX
$714M
$5K ﹤0.01%
712
CPE
416
DELISTED
Callon Petroleum Company
CPE
$5K ﹤0.01%
399
ASIX icon
417
AdvanSix
ASIX
$555M
$4K ﹤0.01%
212
-65
-23% -$1.11K
HPQ icon
418
HP
HPQ
$24.6B
$4K ﹤0.01%
166
+1
+0.6% +$21
TTOO
419
DELISTED
T2 Biosystems, Inc
TTOO
$4K ﹤0.01%
1
ETTX
420
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$4K ﹤0.01%
1,448
CNDT icon
421
Conduent
CNDT
$245M
$3K ﹤0.01%
530
HPE icon
422
Hewlett Packard
HPE
$62.4B
$2K ﹤0.01%
160
+2
+1% +$21
OIH icon
423
VanEck Oil Services ETF
OIH
$2.01B
$2K ﹤0.01%
16
-17
-52% -$2.16K
WAB icon
424
Wabtec
WAB
$49.4B
$2K ﹤0.01%
21
NBRV
425
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2K ﹤0.01%
40

Similar funds

Bollard Group's Q4 2020 Portfolio in Review

As of Q4 2020, Bollard Group held 456 positions worth $2.69B, down 3.2% from $2.78B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Bollard Group withdrew a net $179M in Q4 2020, closing 15 positions and reducing 132 holdings. Its most notable exit was Sphere Entertainment, an estimated $1.71M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 48% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Bollard Group opened a new position in Vanguard Morningstar Total Stock Market ETF worth $643K.

  • Bollard Group's largest Q4 2020 buy was Vanguard Morningstar Total Stock Market ETF: 3,302 shares worth $643K.
  • Bollard Group added most to Madison Square Garden in Q4 2020, an estimated $8.89M increase.
  • Bollard Group's biggest Q4 2020 reduction was Boston Scientific, cutting an estimated $26.2M.
  • Bollard Group fully exited Sphere Entertainment in Q4 2020, selling an estimated $1.71M.
  • Bollard Group's ten largest holdings make up 65% of its $2.69B portfolio in Q4 2020.
  • Bollard Group opened 11 new positions and closed 15 in Q4 2020.
  • Bollard Group's portfolio value fell 3.2% quarter-over-quarter to $2.69B.

Based on Bollard Group's 13F filing for Q4 2020, filed 4 Feb 2021.